We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Tissue-Specific Vesicle Isolation Expands Molecular Insights Into Liver Disease

By LabMedica International staff writers
Posted on 14 Oct 2026

Liver disease can produce overlapping molecular signals from cirrhosis and hepatocellular carcinoma, complicating blood-based analysis. More...

Liquid biopsy approaches that examine extracellular vesicles face an additional challenge: determining which tissues released them. This lack of tissue specificity also limits the interpretation of microRNA biomarkers when their source cannot be established. Now, a newly developed tissue-specific extracellular vesicle platform is designed to reveal liver-derived disease biology.

Mursla Bio (Cambridge, UK) announced the publication of validation data for its tissue-specific extracellular vesicle platform, built on NEXPLOR technology. The platform is designed to isolate extracellular vesicles originating from a selected tissue, with an initial focus on those released by hepatocytes in the liver. By linking these vesicles to their tissue of origin, the approach supports a new class of liquid biopsy intended to analyze multiomic disease biology from living cells within a chosen tissue.

To evaluate this selectivity, the study assessed whether NEXPLOR could enrich hepatocyte-derived extracellular vesicles over those from lung, kidney, breast, adipose and muscle tissues, as well as the blood cells that dominate plasma. Following selective enrichment, the multiomic content of the hepatocyte-derived fraction was compared with bulk extracellular vesicle preparations from the same clinical plasma samples, each measuring less than 2 mL. These paired comparisons used samples from patients with hepatocellular carcinoma or cirrhosis and from healthy donors.

The hepatocyte-derived fraction identified 57% more proteins than paired bulk extracellular vesicle preparations and showed better reproducibility. Differences also emerged in the types of proteins detected: bulk preparations were dominated by liver-secreted plasma proteins, including albumin, whereas the hepatocyte-derived fraction was enriched for membrane, cytosolic and mitochondrial proteins, including extracellular vesicle-defining markers. These differences extended to disease-associated signals. The hepatocyte-derived fraction detected 86 proteins that were unique or significantly increased in liver disease compared with healthy donors, while bulk preparations yielded four unique proteins and no significant differential signal..

Small-RNA sequencing added a second molecular layer to the analysis. In hepatocellular carcinoma versus cirrhosis, hepatocyte-derived extracellular vesicles yielded fewer differentially expressed microRNAs than paired bulk extracellular vesicles, but only the hepatocyte-derived microRNAs mapped to hepatocellular carcinoma signaling. The study was published in the Journal of Extracellular Vesicles, and the technology is a core component of Mursla Bio’s broader tissue-specific extracellular vesicle platform, which also underpins EvoLiver.

“EVs are released by virtually every tissue into the bloodstream. They carry health and disease markers that can be traced back to their origin, much as a tissue biopsy would. To our knowledge, this is the most comprehensive validation to date of a platform for tissue-specific EV isolation from human plasma,” said Dr Tomás Dias, Chief Scientific Officer of Mursla Bio.

“Much of liquid biopsy has focused on measuring more analytes. Our thesis is that biological context matters as much as analytical depth. That is the foundation of EvoLiver and of the precision medicine programs we are building with pharma partners,” said Pierre Arsène, Founder and CEO of Mursla Bio.

Related Links
Mursla Bio


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The MIRAM GAGome Kit quantifies urine CS disaccharides by UHPLC-MS/MS, supporting exploratory and translational research across disease areas. (Photo courtesy of Elypta)

Study Finds Urine Biomarker Score Improves Five-Year Cancer Risk Prediction

Cancer risk stratification in healthy adults often relies on established factors such as age and smoking history. However, several cancers highlighted in the study, including pancreatic, kidney, and brain... Read more

Hematology

view channel
Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.